302440 — SK Bioscience Co Share News
0.000.00%
Last trade - 00:00- KR₩3tn
- KR₩3tn
- KR₩651bn
Brief: SK Bioscience Files For First-In-Human Trial Of Universal Coronavirus Vaccine GBP511 Phase 1/2 Study In Australia
Novavax beats quarterly revenue estimates on milestone payment (updated)
Brief: Sk Bioscience Submits Ind For Phase 1/2 Clinical Trial Of Adjuvanted Influenza Vaccine Candidate
Brief: SK Bioscience - Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine
Brief: SK Bioscience expands influenza vaccine exports to Southern Hemisphere markets
Brief: Sanofi Expands Collaboration With SK Bioscience
Brief: SK Bioscience Receives Approval For Global Clinical Trials Of mRNA Japanese Encephalitis Vaccine Candidate
Brief: Sk Bioscience Co Ltd Q3 Operating Loss 39.6 Billion Won, Swings To Loss From Year Earlier
Brief: Sk Bioscience Announces Approval Of Its Quadrivalent Influenza Vaccine In Indonesia
Brief: Sk Bioscience Q2 Operating Loss 20 Billion Won
Moves: Goldman Sachs names Jaehoon Ahn as South Korea's new investment banking head
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
South Korea's SK Bioscience to buy control of Germany's IDT Biologika for $244 mln (updated)
South Korea's SK Bioscience to buy stake in German vaccine firm IDT Biologika for $244 mln
Brief: SK Bioscience Receives WHO Prequalification For Typhoid Conjugate Vaccine
Brief: Novavax Inc Novavax's Updated Covid-19 Vaccine Receives Emergency Use Authorization In Republic Of Korea
Brief: SK bioscience and Hilleman Laboratories Announce Joint Development of Second-Generation Zaire Ebola Virus Vaccine